BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8410973)

  • 1. Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation.
    Rao CM; Scarborough PE; Kay J; Batley B; Rapundalo S; Klutchko S; Taylor MD; Lunney EA; Humblet CC; Dunn BM
    J Med Chem; 1993 Sep; 36(18):2614-20. PubMed ID: 8410973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of porcine pepsin by two substrate analogues containing statine. The effect of histidine at the P2 subsite on the inhibition of aspartic proteinases.
    Maibaum J; Rich DH
    J Med Chem; 1988 Mar; 31(3):625-9. PubMed ID: 3126296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The three-dimensional X-ray crystal structure of the aspartic proteinase native to Trichoderma reesei complexed with a renin inhibitor CP-80794.
    Pitts JE; Crawford MD; Nugent PG; Wester RT; Cooper JB; Mantyla A; Fagerstrom R; Nevalainen H
    Adv Exp Med Biol; 1995; 362():543-7. PubMed ID: 8540369
    [No Abstract]   [Full Text] [Related]  

  • 4. Design, synthesis, and evaluation of matrix metalloprotease inhibitors bearing cyclopropane-derived peptidomimetics as P1' and P2' replacements.
    Reichelt A; Gaul C; Frey RR; Kennedy A; Martin SF
    J Org Chem; 2002 Jun; 67(12):4062-75. PubMed ID: 12054939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active-site specificity of digestive aspartic peptidases from the four species of Plasmodium that infect humans using chromogenic combinatorial peptide libraries.
    Beyer BB; Johnson JV; Chung AY; Li T; Madabushi A; Agbandje-McKenna M; McKenna R; Dame JB; Dunn BM
    Biochemistry; 2005 Feb; 44(6):1768-79. PubMed ID: 15697202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-function database for active site binding to the aspartic proteinases.
    Rao C; Scarborough PE; Lowther WT; Kay J; Batley B; Rapundalo S; Klutchko S; Taylor MD; Dunn BM
    Adv Exp Med Biol; 1991; 306():143-7. PubMed ID: 1812702
    [No Abstract]   [Full Text] [Related]  

  • 7. The pH dependence of the hydrolysis of chromogenic substrates of the type, Lys-Pro-Xaa-Yaa-Phe-(NO2)Phe-Arg-Leu, by selected aspartic proteinases: evidence for specific interactions in subsites S3 and S2.
    Dunn BM; Valler MJ; Rolph CE; Foundling SI; Jimenez M; Kay J
    Biochim Biophys Acta; 1987 Jun; 913(2):122-30. PubMed ID: 3109484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orally potent human renin inhibitors derived from angiotensinogen transition state: design, synthesis, and mode of interaction.
    Iizuka K; Kamijo T; Harada H; Akahane K; Kubota T; Umeyama H; Ishida T; Kiso Y
    J Med Chem; 1990 Oct; 33(10):2707-14. PubMed ID: 2120440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the binding preferences/specificity in the active site of human cathepsin E.
    Rao-Naik C; Guruprasad K; Batley B; Rapundalo S; Hill J; Blundell T; Kay J; Dunn BM
    Proteins; 1995 Jun; 22(2):168-81. PubMed ID: 7567964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploration of subsite binding specificity of human cathepsin D through kinetics and rule-based molecular modeling.
    Scarborough PE; Guruprasad K; Topham C; Richo GR; Conner GE; Blundell TL; Dunn BM
    Protein Sci; 1993 Feb; 2(2):264-76. PubMed ID: 8443603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substrate specificities and kinetic properties of proteinase A from the yeast Saccharomyces cerevisiae and the development of a novel substrate.
    Kondo H; Shibano Y; Amachi T; Cronin N; Oda K; Dunn BM
    J Biochem; 1998 Jul; 124(1):141-7. PubMed ID: 9644256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, structure-activity, and molecular modeling studies of potent renin inhibitory peptides having N-terminal Nin-For-Trp (Ftr): angiotensinogen congeners modified by P1-P1' Phe-Phe, Sta, Leu psi[CH(OH)CH2]Val or leu psi[CH2NH]Val substitutions.
    Sawyer TK; Pals DT; Mao B; Staples DJ; de Vaux AE; Maggiora LL; Affholter JA; Kati W; Duchamp D; Hester JB
    J Med Chem; 1988 Jan; 31(1):18-30. PubMed ID: 3275777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of potent, selective, and orally active fluorine-containing renin inhibitors.
    Doherty AM; Sircar I; Kornberg BE; Quin J; Winters RT; Kaltenbronn JS; Taylor MD; Batley BL; Rapundalo SR; Ryan MJ
    J Med Chem; 1992 Jan; 35(1):2-14. PubMed ID: 1732531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renin inhibitors containing conformationally restricted P1-P1' dipeptide mimetics.
    Williams PD; Perlow DS; Payne LS; Holloway MK; Siegl PK; Schorn TW; Lynch RJ; Doyle JJ; Strouse JF; Vlasuk GP
    J Med Chem; 1991 Mar; 34(3):887-900. PubMed ID: 2002469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetic and modeling studies of S3-S3' subsites of HIV proteinases.
    Tözsér J; Weber IT; Gustchina A; Bláha I; Copeland TD; Louis JM; Oroszlan S
    Biochemistry; 1992 May; 31(20):4793-800. PubMed ID: 1591240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A structural comparison of 21 inhibitor complexes of the aspartic proteinase from Endothia parasitica.
    Bailey D; Cooper JB
    Protein Sci; 1994 Nov; 3(11):2129-43. PubMed ID: 7703859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin inhibitors containing esters at the P2-position. Oral activity in a derivative of methyl aminomalonate.
    Repine JT; Himmelsbach RJ; Hodges JC; Kaltenbronn JS; Sircar I; Skeean RW; Brennan ST; Hurley TR; Lunney E; Humblet CC
    J Med Chem; 1991 Jul; 34(7):1935-43. PubMed ID: 2066966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aminoethylenes: a tetrahedral intermediate isostere yielding potent inhibitors of the aspartyl protease BACE-1.
    Yang W; Lu W; Lu Y; Zhong M; Sun J; Thomas AE; Wilkinson JM; Fucini RV; Lam M; Randal M; Shi XP; Jacobs JW; McDowell RS; Gordon EM; Ballinger MD
    J Med Chem; 2006 Feb; 49(3):839-42. PubMed ID: 16451048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New inhibitors of human renin that contain novel replacements at the P2 site.
    Doherty AM; Kaltenbronn JS; Hudspeth JP; Repine JT; Roark WH; Sircar I; Tinney FJ; Connolly CJ; Hodges JC; Taylor MD
    J Med Chem; 1991 Apr; 34(4):1258-71. PubMed ID: 1901910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shewasin A, an active pepsin homolog from the bacterium Shewanella amazonensis.
    Simões I; Faro R; Bur D; Kay J; Faro C
    FEBS J; 2011 Sep; 278(17):3177-86. PubMed ID: 21749650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.